CryoPort (CYRX) AI Stock Analysis

• Market Cap: $371.52M
• Dividend Yield: N/A
• Average Volume (3M): 474.26K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.23
• Revenue Growth: -4.53%
• EPS Growth: 5.24%
• Country: US
• Employees: 1,090
• Sector: Industrials
• Sector Strength: 83
• Industry: Integrated Freight & Logistics
• EPS (TTM): -0.28
• Shares Outstanding: 50,137,220
• 10 Day Avg. Volume: 583,004
• 30 Day Avg. Volume: 474,258
• PEG Ratio: 0.26
• Price to Book (P/B): 1.53
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -32.63
• Enterprise Value/Market Cap: 3.36
• Enterprise Value/Revenue: 1.40
• Enterprise Value/Gross Profit: 13.55
• Enterprise Value/Ebitda: -2.98
• 1Y Price Target: $11.00
• Price Target Upside: 48.45% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 8

• Rating: 60 Neutral
• Price Target: $7.00 ▼(-5.53%Downside)

CryoPort's overall stock score is influenced by significant financial challenges and a negative valuation profile. However, strong technical momentum, positive earnings guidance, and strategic corporate moves provide near-term optimism.

Positive Factors

Financial Performance

CYRX reported 1Q25 revenue of $41M, slightly ahead of expectations, with growth led by services up 17%.

Financial Position

The divestiture of CryoPDP to DHL is expected to improve CYRX's balance by reducing debt and generating cash.

Strategic Partnerships

Entering a strategic partnership with DHL aims to strengthen CYRX's position in the APAC and EMEA regions.

Negative Factors

Policy Changes

The full impact of policy changes, including broad-based tariffs and new FDA leadership, is not yet reflected in the current results.

Revenue Estimates

The revenue estimates for 2025 have been reduced from $245M to $169M.

Tariffs Impact

Steel and aluminum tariffs of 25% went into effect, but the full impact is not yet reflected in the results.

CryoPort Business Overview & Revenue Model

Company Description

Cryoport, Inc., a life sciences services company, provides temperature-controlled logistics solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoportal, a cloud-based logistics management platform that supports the management of shipments, which includes order entry, document preparation, customs documentation, courier management, real-time shipment tracking and monitoring, issue resolution, and regulatory compliance requirements; and CryoPort Express Shippers, which is used to ensure that the stability of shipped biologic commodities is maintained throughout the shipping cycle. It also provides information dashboards and validation documentation for shipments through data collected by the SmartPak Condition Monitoring System; and vacuum insulated aluminum dewars and cryogenic freezers systems. In addition, the company offers biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; transportation of frozen biological specimens to and from customer locations; and management of incoming and outgoing biological specimens, as well as provides logistics support and management; and short-term logistics and engineering consulting services. It serves biopharma/pharma, animal health, and human reproductive medicine markets. The company was founded in 1999 and is headquartered in Brentwood, Tennessee.

How the Company Makes Money

CryoPort makes money primarily through its temperature-controlled logistics solutions, which include transportation and storage services for the life sciences sector. The company generates revenue by providing these specialized logistics services to pharmaceutical and biotechnology companies, research institutions, and healthcare providers. Key revenue streams include fees charged for logistics and shipping services, as well as storage and handling of biological materials. CryoPort also benefits from long-term contracts and partnerships with major companies in the life sciences industry, which provide a steady stream of income. Additionally, the company's consulting services contribute to its revenue by offering expertise in supply chain management and regulatory compliance for temperature-sensitive products.

CryoPort Financial Statement Overview

Summary

CryoPort faces financial challenges with declining revenues, persistent losses, and strained cash flow. The balance sheet is stable, but profitability and liquidity issues could impact operations.

Income Statement

CryoPort has experienced declining revenues with a 2% decrease from 2023 to 2024. The company faces significant profitability challenges, with a negative net profit margin of -53.7% and negative EBIT and EBITDA margins, indicating operational inefficiencies. The consistent decline in gross profit margin, standing at 43.6% for 2024, further reflects pressure on maintaining profitability.

Balance Sheet

The balance sheet shows a moderate level of financial stability, with a debt-to-equity ratio of 0.62, indicating a manageable level of leverage. However, the return on equity remains negative, reflecting ongoing net losses. The equity ratio is 57.1%, suggesting a reasonable proportion of equity financing. Overall, the balance sheet exhibits a stable but strained financial position.

Cash Flow

Cash flow analysis reveals negative free cash flow, highlighting liquidity challenges. Although operating cash flow has worsened from -$0.76 million in 2023 to -$16.3 million in 2024, the free cash flow to net income ratio remains negative. The negative operating cash flow to net income ratio also underscores ongoing operational cash burn.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	214.83M	228.38M	233.25M	237.28M	222.61M	78.70M
Gross Profit	92.20M	99.63M	99.33M	103.87M	96.58M	36.33M
EBITDA	-78.23M	-78.61M	-66.36M	-6.19M	-248.91M	-20.31M
Net Income	-109.84M	-114.76M	-99.59M	-37.33M	-275.53M	-32.69M
Balance Sheet
Total Assets	699.84M	703.49M	957.74M	1.04B	1.11B	552.40M
Cash, Cash Equivalents and Short-Term Investments	244.03M	261.75M	456.75M	523.32M	628.80M	93.32M
Total Debt	242.67M	250.70M	416.00M	435.91M	427.06M	130.92M
Total Liabilities	301.03M	301.59M	468.72M	482.91M	471.14M	169.71M
Stockholders Equity	398.81M	401.90M	489.02M	555.84M	641.83M	382.70M
Cash Flow
Free Cash Flow	-25.97M	-33.58M	-45.66M	-26.05M	-16.88M	-24.54M
Operating Cash Flow	-13.06M	-16.32M	-757.00K	-1.85M	8.13M	-14.87M
Investing Cash Flow	176.29M	176.81M	36.05M	-59.68M	-469.25M	-382.31M
Financing Cash Flow	-162.23M	-161.53M	-23.80M	-39.17M	564.34M	385.58M

CryoPort Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 7.41
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CYRX, the sentiment is Positive. The current price of 7.41 is above the 20-day moving average (MA) of 6.69, above the 50-day MA of 6.32, and above the 200-day MA of 6.96, indicating a bullish trend. The MACD of 0.25 indicates Negative momentum. The RSI at 61.85 is Neutral, neither overbought nor oversold. The STOCH value of 85.44 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CYRX.

CryoPort Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RLGT	65 Neutral	$292.76M	17.64	8.09%	―	7.18%	186.98%
CYRX	60 Neutral	$371.52M	―	-24.08%	―	-4.53%	5.24%
Sector *	59 Neutral	AU$1.62B	9.53	11.29%	3.79%	6.45%	5.22%
FWRD	55 Neutral	$765.14M	―	-147.96%	0.86%	50.11%	-682.50%
CRGO	51 Neutral	$126.11M	―	-23.18%	―	49.48%	80.17%
FLX	48 Neutral	$204.04M	124.65	-53.71%	―	-7.95%	-83128.57%
AIRT	45 Neutral	$60.76M	―	-13.52%	―	3.36%	94.32%

CryoPort Corporate Events

CryoPort Sells CRYOPDP Business to DHL Group

On June 11, 2025, Cryoport, Inc. completed the divestiture of its CRYOPDP Business to DHL Group for approximately $200 million, as part of a strategic move to enhance its core capabilities and focus on the rapidly growing regenerative medicine market. This transaction, along with a newly formed strategic partnership with DHL, is expected to strengthen Cryoport’s positioning in the Asia Pacific and EMEA regions, offering enhanced supply chain services and contributing to the company’s long-term profitability goals.

The most recent analyst rating on (CYRX) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on CryoPort stock, see the CYRX Stock Forecast page.

CryoPort Holds 2025 Annual Stockholders Meeting

On June 6, 2025, Cryoport, Inc. held its 2025 Annual Meeting of Stockholders, where several key proposals were voted on. The election of directors resulted in the appointment of six individuals to serve until the 2026 Annual Meeting. Additionally, the appointment of Deloitte and Touche LLP as the independent registered public accounting firm was ratified. Stockholders also approved the compensation of the company’s named executive officers and decided to hold an advisory vote on this compensation annually.

The most recent analyst rating on (CYRX) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on CryoPort stock, see the CYRX Stock Forecast page.

CryoPort Sells CRYOPDP to DHL for $138 Million

On March 31, 2025, Cryoport, Inc. announced the sale of its global specialty courier business, CRYOPDP, to DHL Supply Chain International Holding B.V. for approximately $138 million in cash, based on a total enterprise value of $195 million. This transaction, expected to close in the second or third quarter of 2025, will enhance DHL’s capabilities in specialized pharma logistics and supports its strategy to lead in life science and healthcare logistics. The strategic partnership between Cryoport and DHL aims to strengthen their supply chain service offerings for the global life sciences and healthcare sector, with Cryoport focusing on expanding its business in EMEA and APAC regions.